HCC Stock Recent News

MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has entered into a binding letter of intent (“LOI”) with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC). The celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible to be sold in Europe at the present time.

Warrior Met Coal's strong margins and strategic location contribute to its resilience, with only a 12% stock price decline this year compared to peers' 30-40% drop. Q1 2025 results showed a weak performance, with $39M adjusted EBITDA and negative $68M free cash flow due to soft coking coal prices. Despite weak market conditions, Warrior's liquidity is robust with $617M available, ensuring coverage for Blue Creek's remaining capex and potential losses.

Warrior Met Coal, Inc. (NYSE:HCC ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Brian Chopin - Chief Accounting Officer and Controller Walter Scheller - Chief Executive Officer Dale Boyles - Chief Financial Officer Conference Call Participants Katja Jancic - BMO Capital Markets Nick Giles - B. Riley Securities George Eady - UBS Nathan Martin - The Benchmark Company Operator Good afternoon, my name is Dhawan, and I will be your conference operator today.

Warrior Met Coal (HCC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $2.63 per share a year ago.

BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) today announced results for the first quarter of 2025. Warrior is the leading dedicated U.S.-based producer and exporter of high-quality steelmaking coal for the global steel industry. Warrior reported a net loss for the first quarter of 2025 of $8.2 million, or $0.16 per diluted share, a decrease from net income of $137.0 million, or $2.62 per diluted share, in the first quarter of 2024. The Compa.

BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (NYSE:HCC) (“Warrior” or the “Company”) today announced that its board of directors has approved a regular quarterly cash dividend of $0.08 per share to be paid on May 12, 2025, to stockholders of record as of the close of business on May 5, 2025. About Warrior Warrior is a U.S.-based, environmentally, and socially minded supplier to the global steel industry. It is dedicated entirely to mining non-thermal metallurgical (met) coal used as.

Warrior Met Coal (HCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BROOKWOOD, Ala.--(BUSINESS WIRE)--Warrior Met Coal, Inc. (“Warrior” or NYSE: HCC) today announced that it will hold its first quarter 2025 investor conference call at 4:30 p.m. ET on Wednesday, April 30, 2025. Warrior will release its results following the close of market trading that afternoon. To participate in the conference call, please call 1-844-340-9047 (domestic) or 1-412-858-5206 (international) 10 minutes prior to the start time and reference the Warrior Met Coal conference call. A we.

Warrior Met Coal, Inc. is well-positioned to weather current low coal prices due to its low-cost production and strong balance sheet, with Blue Creek set to enhance margins and production. Despite current oversupply and weak market conditions, long-term demand for metallurgical coal is expected to rise, driven by emerging markets like India and the green energy transition. The Blue Creek project, on time and on budget, will significantly boost HCC's production and margins, making it a valuable long-term investment below $50/share.

• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC) • Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial • Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis (FAP)